

# Serine/Threonine Protein Kinase Pim 1 - Pipeline Review, H2 2020

<https://marketpublishers.com/r/SB4E8FE2CC99EN.html>

Date: July 2020

Pages: 54

Price: US\$ 3,500.00 (Single User License)

ID: SB4E8FE2CC99EN

## Abstracts

Serine/Threonine Protein Kinase Pim 1 - Pipeline Review, H2 2020

### SUMMARY

According to the recently published report 'Serine/Threonine Protein Kinase Pim 1 - Pipeline Review, H2 2020'; Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) pipeline Target constitutes close to 15 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes.

Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) - Proto-oncogene serine/threonine-protein kinase Pim-1 is an enzyme encoded by the PIM1 gene. It promotes cell cycle progression and tumorigenesis by down-regulating expression of a regulator of cell cycle progression CDKN1B at both transcriptional and post-translational levels. It mediates survival signaling through phosphorylation of BAD which induces release of the anti-apoptotic protein Bcl-X (L)/BCL2L1. It phosphorylation of MAP3K5, another proapoptotic protein by PIM1 significantly decreases MAP3K5 kinase activity and inhibits MAP3K5-mediated phosphorylation of JNK and JNK/p38MAPK subsequently reducing caspase-3 activation and cell apoptosis.

The report 'Serine/Threonine Protein Kinase Pim 1 - Pipeline Review, H2 2020' outlays comprehensive information on the Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules

developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 7 and 3 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 2 molecules, respectively. Report covers products from therapy areas Oncology, Cardiovascular, Immunology and Respiratory which include indications Hematological Tumor, Prostate Cancer, Myelofibrosis, Solid Tumor, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Asthma, Bladder Cancer, Chronic Lymphocytic Leukemia (CLL), Diffuse Large B-Cell Lymphoma, Multiple Myeloma (Kahler Disease), Myelodysplastic Syndrome, Myeloproliferative Disorders, Myocardial Infarction, Non-Small Cell Lung Carcinoma, Peanut Allergy, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Primary Myelofibrosis, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Secondary Myelofibrosis and Triple-Negative Breast Cancer (TNBC).

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1)

The report reviews Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects

The report assesses Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) targeted therapeutics

## **REASONS TO BUY**

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope



## Contents

Introduction

Global Markets Direct Report Coverage

Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) -  
Overview

Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) -  
Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) -  
Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) -  
Companies Involved in Therapeutics Development

Amgen Inc

CardioCreate Inc

Incyte Corp

Inflection Biosciences Ltd

NewBay Medical Technology Co Ltd

Novartis AG

Sanofi

SARomics Biostructures AB

Tolero Pharmaceuticals Inc

Vortex Biotechnology Corp

Yakult Honsha Co Ltd

Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) -  
Drug Profiles

Drugs to Inhibit PIM1 Kinase for Asthma and Peanut Allergy - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GDC-0570 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate PIM1 for Myocardial Infarction - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IBL-100 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) -  
Dormant Products

Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) -  
Discontinued Products

Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) -  
Product Development Milestones

Featured News & Press Releases

May 29, 2020: Tolero Pharmaceuticals presents findings from first clinical studies  
evaluating investigational agent TP-3654 in patients with advanced solid tumors at  
ASCO Virtual Annual Meeting 2020

Apr 06, 2020: Boston Biomedical announces first patient dosed in phase 1 study of  
investigational agent TP-3654 in patients with myelofibrosis

May 14, 2019: Tolero Pharmaceuticals announces first patient dosed in phase 1 study  
of investigational agent TP-3654 in patients with advanced solid tumors

Oct 23, 2017: Tolero Pharma To Present Preclinical Data Supporting Development of  
Cancer Drug Candidate TP-3654 for Myc-dependent Triple Negative Breast Cancer

Oct 05, 2017: Tolero Pharma to Deliver Keynote Presentations at 9th International  
Conference on Leukemia and Hematologic Oncology

Jun 30, 2014: Tolero's PIM Kinase Inhibitor Demonstrates Promising Activity in  
Preclinical Models of Urothelial Carcinoma

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2020  
Number of Products under Development by Therapy Areas, H2 2020  
Number of Products under Development by Indications, H2 2020  
Number of Products under Development by Indications, H2 2020 (Contd..1), H2 2020  
Number of Products under Development by Companies, H2 2020  
Products under Development by Companies, H2 2020  
Products under Development by Companies, H2 2020 (Contd..1), H2 2020  
Number of Products under Investigation by Universities/Institutes, H2 2020  
Products under Investigation by Universities/Institutes, H2 2020  
Number of Products by Stage and Mechanism of Actions, H2 2020  
Number of Products by Stage and Route of Administration, H2 2020  
Number of Products by Stage and Molecule Type, H2 2020  
Pipeline by Amgen Inc, H2 2020  
Pipeline by CardioCreate Inc, H2 2020  
Pipeline by Incyte Corp, H2 2020  
Pipeline by Inflection Biosciences Ltd, H2 2020  
Dormant Products, H2 2020  
Dormant Products, H2 2020 (Contd..1), H2 2020  
Discontinued Products, H2 2020

## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2020

Number of Products under Development by Therapy Areas, H2 2020

Number of Products under Development by Top 10 Indications, H2 2020

Number of Products by Mechanism of Actions, H2 2020

Number of Products by Stage and Mechanism of Actions, H2 2020

Number of Products by Top 10 Molecule Types, H2 2020

Number of Products by Stage and Top 10 Molecule Types, H2 2020

### COMPANIES MENTIONED

Amgen Inc

CardioCreate Inc

Incyte Corp

Inflection Biosciences Ltd

NewBay Medical Technology Co Ltd

Novartis AG

Sanofi

SARomics Biostructures AB

Tolero Pharmaceuticals Inc

Vortex Biotechnology Corp

Yakult Honsha Co Ltd



## I would like to order

Product name: Serine/Threonine Protein Kinase Pim 1 - Pipeline Review, H2 2020

Product link: <https://marketpublishers.com/r/SB4E8FE2CC99EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/SB4E8FE2CC99EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970